A5076294654- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Cancer Immunotherapy and Biomarkers
- Clinical practice guidelines implementation
- Complementary and Alternative Medicine Studies
Guy's and St Thomas' NHS Foundation Trust
2020-2024
King's College London
2023
St Thomas' Hospital
2020
Linked Comment:Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online
The article provides a pragmatic update of the British Association Dermatologists guidelines for biologic therapy psoriasis.
Abstract Background Biologic therapies have led to increasing numbers of patients with psoriasis who clear or nearly skin. It is current practice continue biologic therapy indefinitely in these patients, which contributes a substantial long-term drug and healthcare burden. ‘As needed’ may address this; however, our understanding patient clinician perceptions this strategy limited. Objectives The aim mixed-methods study was gain insight into the perspectives both clinicians regarding...
Serum adalimumab concentration is a biomarker of treatment response but therapeutic drug monitoring (TDM) yet to be implemented in routine psoriasis care. We incorporated TDM national specialized service and evaluated it using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) implementation science framework. undertook pre-implementation planning (validating local assays) interventions targeted patients (pragmatic sampling at reviews), clinicians (introduction...
Abstract Adalimumab is widely used in the treatment of immune-mediated inflammatory diseases. It highest-spend drug National Health Service, costing more than £400 million annually. In 2018, adalimumab biosimilars became available, leading to substantial cost savings. However, patient tolerability remains underexplored. We evaluated biosimilar therapy (Idacio®) patients who were switched from Humira® a large dermatology and rheumatology tertiary centre. identified all issued with...